Eli Lilly is trading 4.35% higher at $1,294.30, supported by healthcare strength; no single catalyst is confirmed. - Healthcare rose 2.12% during the regular session. - Earlier reports cited positive Phase 3 pediatric ulcerative-colitis results for Omvoh and an EMA committee recommendation for oral obesity drug Foundayo; both predated October 20. - Lilly announced an up-to-$1.1 billion Metis TechBio delivery collaboration October 19; reporting does not establish it as the direct cause of the intraday jump.